Market Strategies International | Market Research and Consulting - Knowledge Center - Syndicated Studies

Syndicated Studies

2009 MSImage Oncology & Hematology Study

Market Strategies has released its fourth annual MSImage Oncology & Hematology Study which identifies those pharmaceutical/biopharmaceutical companies that oncologists and hematologists perceive to have the best overall image.

The study was conducted with 465 physicians, who evaluated more than 30 pharmaceutical sales professionals, corporate equity and R&D attributes, to determine which measures drive a pharmaceutical/biopharmaceutical company’s image and performance.

In this study physicians identified several information-related attributes as critical drivers of image. While physicians want to hear more about new clinical information and emerging research, it is more difficult than ever for sales reps to get access to these physicians.

The MSImage Oncology & Hematology Study helps such companies better understand their strengths and weaknesses among key stakeholders. It can be used by companies to effectively drive performance measures, influencing decision makers to engage in more positive behaviors toward high performing companies. It also can be used to develop strategies for sales reps to become more effective in the present and future.

This emphasis on image leadership can lead to increased customer loyalty, actual and future purchase intentions, peer recommendations and a general willingness to participate in pharmaceutical/biopharmaceutical programs, clinical trials and a willingness to see more sales reps from that company.

Benefits to purchasing the study include:

Identification of which company activities impact oncology/hematology stakeholders’ perceptions, thereby driving overall corporate image
Detailed results among top scoring companies and why Genentech, Novartis, Celgene, Sanofi-Aventis, AstraZeneca, Amgen, Eli Lilly/ImClone and others lead the way
Identification of the relative impacts of drivers on corporate image and key attributes.
The ability to benchmark against competitors on attribute performance and the comparison of relative positions companies have on each attribute
Detailed benchmarking to past studies is provided

With your subscription to the 2009 MSImage Oncology & Hematology Study you will receive:

A detailed presentation report complete with strategic insights and recommendations:
- All Company 2009 master card which includes the 2009 scores on key measures, statistical significance between companies on these measures, and ranks for all companies included in this year’s study
- Competitive Set 2009 master card which includes the 2009 scores and statistical significance between companies for your competitive set on key measures.
- Competitive Set Trend master card which includes the scores for your competitive set for 2007, 2008 and 2009 on key measures. Color coding is used to indicate significant differences between 2008 and 2009 data.
On site customized presentation

For additional information on the 2009 MSImage Oncology and Hematology study, as well as other MSImage studies such as the ASCO syndicated study, please contact: Oncology@marketstrategies.com or corpmktg@marketstrategies.com.